A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis

NCT05044026 · clinicaltrials.gov ↗

COMPLETED

Status

1012

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis

Interventions

OTHER: Jakavi

Sponsor

Novartis Pharmaceuticals